We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
-12.31%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.52B
AUM Growth
-$397M
(-21%)
Cap. Flow
-$26.5M
Cap. Flow
% of AUM
-1.74%
Top 10 Holdings %
Top 10 Hldgs %
80.05%
Holding
36
New
2
Increased
1
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Champions Oncology
CSBR
|
+$10.2M |
| 2 |
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
|
+$1.77M |
| 3 |
AKTX
Akari Therapeutics
AKTX
|
+$402K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
|
+$37.6M |
| 2 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
+$1.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.83% |
| 2 | Communication Services | 10.44% |
| 3 | Technology | 8.46% |
| 4 | Consumer Discretionary | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Aurinia Pharmaceuticals
AUPH
$1.91B
| $7.23M | 0.48% |
2,546,843
| – | – |
|
|
DZSI
27
DELISTED
DZS Inc. Common Stock
DZSI
| $6.55M | 0.43% |
956,258
| – | – |
|
|
ROKA
28
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
| $6.28M | 0.41% |
322,043
| – | – |
|
|
ECOM
29
DELISTED
CHANNELADVISOR CORPORATION
ECOM
| $5.53M | 0.36% |
556,692
| – | – |
|
|
ARQL
30
DELISTED
Arqule Inc
ARQL
| $4.71M | 0.31% |
2,520,316
| – | – |
|
|
VIRX
31
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.61M | 0.3% |
27,094
+4,907
| +22% | +$1.77M |
|
32
Gyre Therapeutics
GYRE
$641M
| $3.04M | 0.2% |
5,799
| – | – |
|
|
PRTK
33
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $2.38M | 0.16% |
125,004
-48,888
| -28% | -$1.22M |
|
|
AGRX
34
DELISTED
Agile Therapeutics
AGRX
| $900K | 0.06% |
67
| – | – |
|
|
AKTX
35
Akari Therapeutics
AKTX
$13.8M
| $645K | 0.04% |
+34
| New | +$402K |
|
|
VTAE
36
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| – | – |
-2,613,199
| Closed | -$37.6M |
|
Similar funds
NM
SLF
CCIA
SW
CGH
PWP
CIP
GD
NEA Management Company's Q3 2015 Portfolio in Review
As of Q3 2015, NEA Management Company held 36 positions worth $1.52B, down 21% from $1.91B the previous quarter. Its ten largest holdings account for 80% of the portfolio.
NEA Management Company's Q3 2015 filing shows 2 new, 1 increased, 1 reduced and 1 closed positions. Its largest new stake was Champions Oncology: 1,562,500 shares worth $8.36M. The largest sale was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $37.6M.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 72% a quarter earlier, followed by Communication Services and Technology.
- NEA Management Company's largest Q3 2015 buy was Champions Oncology: 1,562,500 shares worth $8.36M.
- NEA Management Company added most to Viracta Therapeutics, Inc. Common Stock in Q3 2015, an estimated $1.77M increase.
- NEA Management Company's biggest Q3 2015 reduction was Paratek Pharmaceuticals, Inc., cutting an estimated $1.22M.
- NEA Management Company fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2015, selling an estimated $37.6M.
- NEA Management Company's ten largest holdings make up 80% of its $1.52B portfolio in Q3 2015.
- NEA Management Company opened 2 new positions and closed 1 in Q3 2015.
- NEA Management Company's portfolio value fell 21% quarter-over-quarter to $1.52B.
Based on NEA Management Company's 13F filing for Q3 2015, filed 10 Nov 2015.